Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedNov 01, 2025
DataAggregated Company Financials
Companies63
  • 7D-2.2%
  • 3M17.9%
  • 1Y-4.0%
  • YTD1.5%

Over the last 7 days, the Life Sciences industry has dropped 2.2%, driven by Danaher declining 3.4%. On the other hand Illumina is actually up 23%. The industry has fallen 4.0% in the last year. Earnings are forecast to grow by 17% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 01 Nov 2025US$639.2bUS$145.4bUS$12.2b36x52.6x4.4x
Mon, 29 Sep 2025US$552.3bUS$144.3bUS$14.6b29.4x37.9x3.8x
Wed, 27 Aug 2025US$583.2bUS$144.1bUS$14.5b28.8x40.2x4x
Fri, 25 Jul 2025US$565.9bUS$143.6bUS$8.8b41.6x64.4x3.9x
Sun, 22 Jun 2025US$516.2bUS$142.9bUS$9.2b35.3x56.3x3.6x
Tue, 20 May 2025US$519.6bUS$142.7bUS$9.1b33.4x57.2x3.6x
Thu, 17 Apr 2025US$517.3bUS$142.6bUS$10.0b35x52x3.6x
Sat, 15 Mar 2025US$581.3bUS$143.1bUS$9.8b38.6x59.5x4.1x
Mon, 10 Feb 2025US$658.3bUS$143.1bUS$11.1b38.1x59.3x4.6x
Wed, 08 Jan 2025US$673.1bUS$142.4bUS$10.2b43.9x66x4.7x
Fri, 06 Dec 2024US$671.2bUS$142.4bUS$10.2b43.6x65.7x4.7x
Sun, 03 Nov 2024US$689.4bUS$142.2bUS$8.9b39.1x77.3x4.8x
Tue, 01 Oct 2024US$748.6bUS$141.8bUS$8.5b39x88.1x5.3x
Thu, 29 Aug 2024US$745.7bUS$141.8bUS$8.5b37.7x87.8x5.3x
Sat, 27 Jul 2024US$716.0bUS$141.0bUS$12.5b37.3x57.4x5.1x
Mon, 24 Jun 2024US$694.3bUS$141.3bUS$12.2b38.6x57x4.9x
Wed, 22 May 2024US$739.8bUS$141.5bUS$12.4b38.5x59.5x5.2x
Fri, 19 Apr 2024US$682.0bUS$142.0bUS$12.8b41x53.3x4.8x
Sun, 17 Mar 2024US$742.0bUS$142.1bUS$12.8b43.9x57.8x5.2x
Tue, 13 Feb 2024US$709.9bUS$141.9bUS$12.7b39.2x55.8x5x
Thu, 11 Jan 2024US$692.8bUS$153.9bUS$14.2b36.6x48.9x4.5x
Sat, 09 Dec 2023US$648.8bUS$153.7bUS$14.0b35.2x46.3x4.2x
Mon, 06 Nov 2023US$595.2bUS$153.9bUS$11.0b31.5x54x3.9x
Wed, 04 Oct 2023US$640.4bUS$154.6bUS$11.2b32.3x57.2x4.1x
Fri, 01 Sep 2023US$733.5bUS$154.6bUS$11.2b32.9x65.4x4.7x
Sun, 30 Jul 2023US$734.3bUS$154.7bUS$11.6b31.5x63.2x4.7x
Tue, 27 Jun 2023US$687.9bUS$152.4bUS$12.5b29.3x55x4.5x
Thu, 25 May 2023US$671.4bUS$152.2bUS$12.5b27.8x53.7x4.4x
Sat, 22 Apr 2023US$728.5bUS$154.6bUS$10.8b29.9x67.4x4.7x
Mon, 20 Mar 2023US$700.9bUS$154.5bUS$10.8b27.3x64.8x4.5x
Wed, 15 Feb 2023US$749.4bUS$154.2bUS$8.6b32.4x87.2x4.9x
Fri, 13 Jan 2023US$756.5bUS$155.3bUS$8.5b30.4x88.7x4.9x
Sun, 11 Dec 2022US$761.9bUS$155.1bUS$8.8b28.4x86.8x4.9x
Tue, 08 Nov 2022US$707.8bUS$154.9bUS$9.1b26.4x78.1x4.6x
Price to Earnings Ratio

78.1x


Total Market Cap: US$707.8bTotal Earnings: US$9.1bTotal Revenue: US$154.9bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 61.8x202320242025
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 52.6x which is lower than its 3-year average PE of 61.8x.
  • The industry is trading close to its 3-year average PS ratio of 4.5x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 10% per year over the last three years.
  • Meanwhile revenues for these companies have declined 2.1% per year.
  • This means that less sales are being generated overall, but since cost of doing business is lower, profits have been increasing.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.46%
Healthcare-0.75%
Life Sciences-2.23%
Clinical Research and Equipment-2.23%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ILMN IlluminaUS$123.5423.4%
+US$3.6b		-17.5%PE27x
TEM Tempus AIUS$89.850.7%
+US$107.7m		95.1%PS16.4x
PACB Pacific Biosciences of CaliforniaUS$2.3415.8%
+US$96.1m		-4.1%PS4.5x
ADPT Adaptive BiotechnologiesUS$17.360.8%
+US$21.3m		226.9%PS12.9x
LFCR Lifecore BiomedicalUS$7.196.0%
+US$15.4m		22.4%PS2.1x

Latest News

AVTR
US$11.82
Avantor
7D
-23.2%
1Y
-47.0%

Avantor, Inc. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts

Nov 01
Avantor, Inc. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
ILMN
US$123.54
Illumina
7D
23.4%
1Y
-17.5%
LFCR
US$7.19
Lifecore Biomedical
7D
6.0%
1Y
22.4%
RGEN
US$149.06
Repligen
7D
-10.4%
1Y
7.5%

Repligen Corporation Just Beat EPS By 18%: Here's What Analysts Think Will Happen Next

Oct 31
Repligen Corporation Just Beat EPS By 18%: Here's What Analysts Think Will Happen Next
IQV
US$216.46
IQVIA Holdings
7D
-1.8%
1Y
3.5%
HBIO
US$0.52
Harvard Bioscience
7D
26.6%
1Y
-78.5%
TMO
US$567.39
Thermo Fisher Scientific
7D
-0.9%
1Y
1.7%
RVTY
US$93.59
Revvity
7D
-5.4%
1Y
-22.7%
WST
US$282.07
West Pharmaceutical Services
7D
-5.2%
1Y
-10.9%
TEM
US$89.85
Tempus AI
7D
0.7%
1Y
95.1%

Advances In Precision Medicine And AI Will Reshape Cancer Care Futures

Analysts have raised their price target for Tempus AI from $77.55 to $82.50, citing stronger confidence in revenue growth and profitability projections. What's in the News Tempus AI and Whitehawk Therapeutics announced a multi-year collaboration to use Tempus' real-world dataset to advance biomarker-driven research and enhance oncology clinical trial design.
PACB
US$2.34
Pacific Biosciences of California
7D
15.8%
1Y
-4.1%
HYFT
US$1.87
MindWalk Holdings
7D
14.0%
1Y
347.9%
DHR
US$215.38
Danaher
7D
-3.4%
1Y
-13.1%

Analyst Commentary Highlights Mixed Sentiment and Minor Valuation Adjustments for Danaher

Analysts have marginally raised their fair value estimate for Danaher to $247.30 from $244.50, citing improved profit margins and earnings quality. However, near-term growth expectations remain tempered by ongoing market uncertainties.
ADPT
US$17.36
Adaptive Biotechnologies
7D
0.8%
1Y
226.9%

EMR Integration And Partnerships Will Reshape Clinical Diagnostics

Analysts have raised their price target for Adaptive Biotechnologies from $14.86 to $16.00. They cite the company’s strong positioning in cancer testing and sustained revenue growth potential.
CRL
US$180.07
Charles River Laboratories International
7D
-8.6%
1Y
-0.5%

Advanced Therapeutics Adoption Will Transform Preclinical Capabilities

Charles River Laboratories International's analyst price target increased from approximately $179.73 to $185.87. This reflects analysts' improved outlook due to signs of stabilizing demand, easing industry overhangs, and positive trends in preclinical research spending.
NAUT
US$1.33
Nautilus Biotechnology
7D
9.0%
1Y
-49.0%